Renovaro Biosciences (RENB) 10-Q 9 Mar 23 2023 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Dec. 31, 2022	Mar. 09, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--06-30
Entity File Number	001-38758
Entity Registrant Name	Enochian Biosciences Inc.
Entity Central Index Key	0001527728
Entity Tax Identification Number	45-2559340
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1927 Paseo Rancho Castillo
Entity Address, City or Town	Los Angeles
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	90032
City Area Code	(305)
Local Phone Number	918-1980
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	ENOB
Security Exchange Name	NASDAQ
Entity Current Reporting Status	No
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		55,705,521

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2022	Jun. 30, 2022
CURRENT ASSETS:
Cash	$ 4,118,896	$ 9,172,142
Prepaids and other assets	1,270,575	392,996
Total Current Assets	5,389,471	9,565,138
Property and equipment, net	555,916	586,536
OTHER ASSETS:
Definite life intangible assets, net	42,084	44,268
Indefinite life intangible assets, net	61,571,000	61,571,000
Goodwill	11,640,000	11,640,000
Deposits and other assets	61,936	68,635
Operating lease right-of-use assets	1,013,256	1,157,086
Total Other Assets	74,328,276	74,480,989
TOTAL ASSETS	80,273,663	84,632,663
CURRENT LIABILITIES:
Accounts payable – trade	4,555,226	1,401,867
Accrued expenses	932,603	1,031,462
Other current liabilities	875,415	220,685
Contingent consideration liability		2,343,318
Notes payable, net	4,726,390
Convertible notes payable		1,200,000
Current portion of operating lease liabilities	202,370	253,636
Total Current Liabilities	11,292,004	6,450,968
NON-CURRENT LIABILITIES:
Convertible notes payable	1,200,000
Notes payable, net		4,577,148
Operating lease liabilities, net of current portion	882,303	985,699
Total Non-Current Liabilities	2,082,303	5,562,847
Total Liabilities	13,374,307	12,013,815
Commitments and Contingencies
STOCKHOLDERS’ EQUITY:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock, par value $0.0001, 100,000,000 shares authorized, 55,705,521 shares issued and outstanding at December 31, 2022, and 53,007,082 shares issued and outstanding at June 30, 2022	5,572	5,302
Additional paid-in capital	283,426,764	276,989,179
Accumulated deficit	(216,502,705)	(204,345,197)
Accumulated other comprehensive loss	(30,275)	(30,436)
Total Stockholders’ Equity	66,899,356	72,618,848
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 80,273,663	$ 84,632,663

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2022	Jun. 30, 2022
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common Stock, shares issued	55,705,521	53,007,082
Common stock, shares outstanding	55,705,521	53,007,082

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Operating Expenses
General and administrative	$ 4,013,063	$ 3,961,764	$ 8,569,903	$ 8,379,268
Research and development	325,959	2,337,222	2,931,334	5,392,658
Depreciation and amortization	28,844	31,805	57,245	63,538
Total Operating Expenses	4,367,866	6,330,791	11,558,482	13,835,464
LOSS FROM OPERATIONS	(4,367,866)	(6,330,791)	(11,558,482)	(13,835,464)
Other Income (Expense)
Loss on extinguishment of contingent consideration			(419,182)
Change in fair value of contingent consideration		(167,255)		(2,991,897)
Interest expense	(92,892)	(93,382)	(188,477)	(183,121)
Gain on currency transactions				9
Interest and other income	3,010	8,487	8,633	15,597
Total Other Income (Expense)	(89,882)	(252,150)	(599,026)	(3,159,412)
Loss Before Income Taxes	(4,457,748)	(6,582,941)	(12,157,508)	(16,994,876)
Income Tax (Provision) Benefit				(34)
NET LOSS	$ (4,457,748)	$ (6,582,941)	$ (12,157,508)	$ (16,994,910)
BASIC AND DILUTED LOSS PER SHARE	$ (0.08)	$ (0.13)	$ (0.22)	$ (0.33)
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - BASIC AND DILUTED	55,509,239	52,321,982	55,304,356	52,270,821

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Net Loss	$ (4,457,748)	$ (6,582,941)	$ (12,157,508)	$ (16,994,910)
Other Comprehensive Income (Loss)
Foreign currency translation, net of taxes	7,915	(3,990)	161	(7,983)
Comprehensive Loss	$ (4,449,833)	$ (6,586,931)	$ (12,157,347)	$ (17,002,893)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Beginning balance, value at Jun. 30, 2021	$ 5,222	$ 265,580,356	$ (90,911,805)	$ (10,834)	$ 174,662,939
Beginning Balance, Shares at Jun. 30, 2021	52,219,661
Stock-Based Compensation		2,727,975			2,727,975
Net Loss			(10,411,969)		(10,411,969)
Foreign currency translation adjustment				(3,993)	(3,993)
Ending balance, value at Sep. 30, 2021	$ 5,222	268,308,331	(101,323,774)	(14,827)	166,974,952
Ending Balance, Shares at Sep. 30, 2021	52,219,661
Stock issued pursuant to warrants exercised	$ 10	129,990			130,000
Stock issued pursuant to warrants exercised, Shares	100,000
Shares issued pursuant to LPC purchase agreement	$ 28	3,048,311			3,048,339
Shares issued pursuant to LPC purchase agreement, shares	277,340
Stock-Based Compensation		2,043,292			2,043,292
Shares issued for fully vested RSUs		9,811			9,811
Shares issued for fully vested RSUs, shares	1,266
Restricted shares converted to shares for services rendered	$ 3	(3)
Restricted shares converted to shares for services rendered, shares	35,000
Net Loss			(6,582,941)		(6,582,941)
Foreign currency translation adjustment				(3,990)	(3,990)
Ending balance, value at Dec. 31, 2021	$ 5,263	273,539,732	(107,906,715)	(18,817)	165,619,463
Ending Balance, Shares at Dec. 31, 2021	52,633,267
Beginning balance, value at Jun. 30, 2022	$ 5,302	276,989,179	(204,345,197)	(30,436)	72,618,848
Beginning Balance, Shares at Jun. 30, 2022	53,007,082
Stock issued pursuant to warrants exercised	$ 125	1,624,875			1,625,000
Stock issued pursuant to warrants exercised, Shares	1,250,000
Shares issued for earn-out	$ 125	2,762,375			2,762,500
Shares issued for Earn-out, shares	1,250,000
Stock-Based Compensation		1,026,008			1,026,008
Net Loss			(7,699,760)		(7,699,760)
Foreign currency translation adjustment				(7,754)	(7,754)
Ending balance, value at Sep. 30, 2022	$ 5,552	282,402,437	(212,044,957)	(38,190)	70,324,842
Ending Balance, Shares at Sep. 30, 2022	55,507,082
Shares issued in lieu of interest on $1.2 million note payable extension	$ 20	204,372			204,392
Shares issued in lieu of interest on $1.2 million note payable extension, shares	198,439
Stock-Based Compensation		819,955			819,955
Net Loss			(4,457,748)		(4,457,748)
Foreign currency translation adjustment				7,915	7,915
Ending balance, value at Dec. 31, 2022	$ 5,572	$ 283,426,764	$ (216,502,705)	$ (30,275)	$ 66,899,356
Ending Balance, Shares at Dec. 31, 2022	55,705,521

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	6 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (12,157,508)	$ (16,994,910)
ADJUSTMENTS TO RECONCILE NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES:
Depreciation and amortization	57,245	63,538
Loss on extinguishment of contingent consideration liability	419,182
Change in contingent consideration liability		2,991,897
Stock based compensation expense	1,845,963	4,771,267
Amortization of discount of notes payable	149,242	148,548
Changes in assets and liabilities:
Other receivables	46	1,640
Prepaid expenses/deposits	425,233	(11,812)
Accounts payable	3,153,358	(153,810)
Accrued expenses	(68,554)	(677,939)
Other current liabilities	(18,520)	(30,004)
Operating leases, net	(10,832)	(5,566)
NET CASH USED IN OPERATING ACTIVITIES	(6,205,145)	(9,897,151)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(23,633)	(5,156)
NET CASH USED IN INVESTING ACTIVITIES	(23,633)	(5,156)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of warrants	1,625,000	130,000
Repayment of finance agreement	(466,625)	(227,598)
Proceeds from LPC equity agreement		3,048,339
NET CASH PROVIDED BY FINANCING ACTIVITIES	1,158,375	2,950,741
Effect of exchange rates on cash	17,157	(4,937)
NET CHANGE IN CASH	(5,053,246)	(6,956,503)
CASH, BEGINNING OF PERIOD	9,172,142	20,664,410
CASH, END OF PERIOD	4,118,896	13,707,907
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Interest	30,332	36,462
Income Taxes		34
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Finance agreement entered into in exchange for prepaid assets	1,139,875	666,875
Shares in lieu of interest on $1.2 million notes payable extension	204,392
Common shares issued for contingent earn out liability	$ 2,762,500

THE BUSINESS AND SUMMARY OF SIG

THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 — THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Business Going Concern 216,502,705 Basis of Presentation Consolidation Reclassification 193,137 242,330 . Accounting Estimates COVID-19 Update The full extent to which the COVID-19 pandemic may impact our business and operations is subject to future developments, which are uncertain and difficult to predict. We continue to monitor the impact of the COVID-19 pandemic on our business and operations and will seek to adjust our activities as appropriate. In addition, the pandemic could result in significant and prolonged disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect the financial resources available to us. Functional Currency & Foreign Currency Translation Cash and Cash Equivalents 3,830,530 8,805,495 Property and Equipment Intangible Assets Definite life intangible assets include patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 350, “Goodwill and Other Intangible Assets”. Intangible assets are recorded at cost. Patent costs consist of costs incurred to acquire the underlying patent. If it is determined that a patent will not be issued, the related remaining capitalized patent costs are charged to expense. Intangible assets are amortized on a straight-line basis over their estimated useful life. The estimated useful life of patents is twenty years from the date of application. Indefinite life intangible assets include license agreements and goodwill. The Company accounts for indefinite life intangible assets in accordance with ASC 350, “Goodwill and Other Intangible Assets”. License agreement costs represent the fair value of the license agreement on the date acquired and are tested annually for impairment, as well as whenever events or changes in circumstances indicate the carrying value may not be recoverable. Goodwill th Impairment of Goodwill and Indefinite Lived Intangible Assets For indefinite-lived intangible assets, such as licenses acquired as an IPR&D asset, on an annual basis we determine the fair value of the asset and record an impairment loss, if any, for the excess of the carrying value of the asset over its fair value. For the year ended June 30, 2022, the carrying value of the licenses acquired as an IPR&D asset exceeded its fair value. Therefore, the Company recorded an impairment loss of $ 93,253,000 The carrying value of IPR&D and goodwill at December 31, 2022, was $ 61,571,000 11,640,000 Impairment of Long-Lived Assets Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell and would no longer be depreciated. The depreciable basis of assets that are impaired and continue in use are their respective fair values. Leases Rent expense for operating leases is recognized on a straight-line basis, unless the operating lease right of use assets have been impaired, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the condensed consolidated statements of operations. For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease right-of-use assets on a straight-line basis over the remaining lease term with rent expense still included in general and administrative expenses in the unaudited condensed consolidated statements of operations. The Company has elected the practical expedient to not separate lease and non-lease components. The Company’s non-lease components are primarily related to property maintenance, insurance, and taxes, which vary based on future outcomes, and thus are recognized in general and administrative expenses when incurred (see Note 6.) Research and Development Expenses 325,959 2,931,334 2,337,222 5,392,658 Income Taxes Loss Per Share 4,833,436 7,125,894 Fair Value of Financial Instruments Stock Options and Restricted Share Units Stock-Based Compensation 819,955 1,845,963 2,043,292 4,771,267 Recently Adopted Accounting Pronouncements

GOING CONCERN

GOING CONCERN	6 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 2 – GOING CONCERN The Company’s consolidated financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the Company has incurred substantial recurring losses from continuing operations, has used cash in the Company’s continuing operations, and is dependent on additional financing to fund operations. The Company incurred a net loss of approximately $ 4,457,748 12,157,508 4,118,896 216,502,705

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	6 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 3 — FAIR VALUE MEASUREMENTS The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC Topic 820, “Fair Value Measurements”. The authoritative guidance among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: ● Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities; ● Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and ● Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. There were no Level 1, 2 or 3 assets, nor any Level 1, 2 or 3 liabilities measured at fair value on a recurring basis as of December 31, 2022.

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	6 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 4 — PROPERTY AND EQUIPMENT Property and equipment consisted of the following: Summary of property and equipment Useful Life December 31, 2022 June 30, 2022 Lab Equipment and Instruments 4 7 $ 570,157 $ 546,524 Leasehold Improvements 10 224,629 224,629 Furniture, Fixtures and Equipment 4 7 172,861 172,861 Total 967,647 944,014 Less Accumulated Depreciation (411,731 ) (357,478 ) Net Property and Equipment $ 555,916 $ 586,536 Depreciation expense amounted to $ 27,338 54,253 27,990 55,796

INTANGIBLE ASSETS

INTANGIBLE ASSETS	6 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 5 — INTANGIBLE ASSETS At December 31, 2022, and June 30, 2022, definite-life intangible assets, net of accumulated amortization, consisted of patents on the Company’s products and processes of $ 42,084 44,268 1,507 2,993 3,814 7,741 At December 31, 2022, and 2021, indefinite life intangible assets consisted of a license agreement classified as In-Process Research and Development (“IPR&D”) intangible assets, which are not amortizable until the intangible asset provides economic benefit, and goodwill. At December 31, 2022, and June 30, 2022, definite and indefinite-life intangible assets consisted of the following: Schedule of life intangible assets Useful Life June 30, Period Change Effect of Currency Translation December 31, Definite Life Intangible Assets Patents 20 $ 279,257 $ — $ 6,163 $ 285,420 Less Accumulated Amortization (234,989 ) (2,993 ) (5,354 ) (243,336 ) Net Definite-Life Intangible Assets $ 44,268 $ (2,993 ) $ 809 $ 42,084 Indefinite Life Intangible Assets License Agreement $ 61,571,000 — — $ 61,571,000 Goodwill 11,640,000 — — 11,640,000 Total Indefinite Life Intangible Assets $ 73,211,000 — — $ 73,211,000 Expected future amortization expense is as follows: Schedule of expected future amortization expense Year ending June 30, 2023 $ 8,883 2024 11,067 2025 11,067 2026 11,067 Total $ 42,084 During February 2018, the Company acquired a License Agreement (as licensee) to an HIV therapy which consists of a perpetual, fully paid-up, royalty-free, sub-licensable, and sole and exclusive worldwide license to research, develop, use, sell, have sold, make, have made, offer for sale, import and otherwise commercialize certain intellectual property in cellular therapies for the prevention, treatment, amelioration of and/or therapy exclusively for HIV in humans, and research and development exclusively relating to HIV in humans. Because the HIV License Agreement is considered an IPR&D intangible asset it is classified as an indefinite life asset that is tested annually for impairment. Impairment – Following the fourth quarter of each year, management performs its annual test of impairment of intangible assets by performing a quantitative assessment and determines if it is more likely than not that the fair value of the asset is greater than or equal to the carrying value of the asset. The results of the quantitative assessment indicated that the carrying value of the licenses acquired as an IPR&D asset exceeded its fair value, due to the sublicensing of ENOB HV-01, which required a different valuation approach and changes in other factors impacting the fair value of the asset. Therefore, an impairment adjustment of $ 93,253,000 No

LEASES

LEASES	6 Months Ended
	Dec. 31, 2022
Leases
LEASES	NOTE 6 — LEASES Operating Leases On November 13, 2017, the Company entered into a Lease Agreement for a term of five years and two months from November 1, 2017, with Plaza Medical Office Building, LLC, a California limited liability company, as landlord, (the “Landlord”), pursuant to which the Company agreed to lease from the Landlord approximately 2,325 rentable square feet. The base rent increased by 3% each year, and ranged from approximately $8,719 per month for the first year to $10,107 per month for the two months of the sixth year. The lease was terminated early without penalties or additional costs as of September 30, 2022, 70,800 On June 19, 2018, the Company entered into a Lease Agreement for a term of ten years from September 1, 2018, with Century City Medical Plaza Land Co., Inc., pursuant to which the Company agreed to lease approximately 2,453 rentable square feet. On February 20, 2019, the Company entered into an Addendum to the original Lease Agreement with an effective date of December 1, 2019, where it expanded the lease area to include another 1,101 square feet for a total rentable 3,554 square feet. The base rent increases by 3% each year, and ranges from $17,770 per month for the first year to $23,186 per month for the tenth year. The equalized monthly lease expense for the term of the lease is $20,050. Sublease Agreement The Company identified and assessed the following significant assumptions in recognizing the right-of-use asset and corresponding liabilities: Expected lease term 4.67 Incremental borrowing rate 4.03 Lease and non-lease components Below are the lease commitments for the next 5 years: Lease commitments Year Ending June 30 th Lease Expense 2023 $ 120,002 2024 246,004 2025 253,384 2026 260,985 2027 313,836 Less imputed interest (109,538 ) Total $ 1,084,673 Sublease Agreement On June 20, 2022, the Company entered into a sublease Agreement with One Health Labs (the “Subtenant”), whereby the Subtenant agreed to lease 3,554 square feet of space currently rented by the Company in Century City Medical Plaza as of June 25, 2022, for a period of 3.5 years with an option to renew for the remaining term of the lease that ends as of June 19, 2028. The base rent is $17,770 per month plus $750 towards utility fees that are part of the original lease agreement and will increase by 3% each year over the term of the sub-lease. The Company received a total of $57,022 on July 1, 2022 after execution of the sublease to cover the first month rent, utility fee and deposit. The first sublease payment began on August 1, 2022. In accordance with ASC Topic 842, the Company treats the sublease as a separate lease, as the Company was not relieved of the primary obligation under the original lease. The Company continues to account for the Century City Medical Plaza lease as a lessee and in the same manner as prior to the commencement date of the sublease. The Company accounts for the sublease as a lessor of the lease. The sublease is classified as an operating lease, as it does not meet the criteria of a sales-type or direct financing lease. The Company will recognize operating income from the sublease on a straight-line basis in its statements of operations over the sublease term. During the three and six months ended December 31, 2022 and 2021, the net operating lease expenses were as follows: Schedule of net operating lease expenses For the Three Months Ended For the Six Months Ended December 31, December 31, 2022 2021 2022 2021 Operating Lease Expense $ 96,730 $ 84,113 $ 140,660 $ 168,196 Sub lease Income (53,310 ) — (106,620 ) — Total Net Lease Expense $ 43,420 $ 84,113 $ 34,040 $ 168,196 Lease expense charged to general and administrative expenses for the three and six months ended December 31, 2022, amounted to $ 43,420 34,040 84,113 168,196

NOTES PAYABLE

NOTES PAYABLE	6 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTE 7 — NOTES PAYABLE Convertible Notes Payable 600,000 0.0001 February 6, 2023 6 The holder of the Convertible Notes had the right at any time prior to the date that is twelve months from issuance to convert all or any part of the outstanding and unpaid principal and all unpaid interest into shares of the Company’s Common Stock. The conversion price was equal to $ 12.00 1,200,000 Effective December 30, 2022 (the “Effective Date”), the Company amended and restated the Convertible Notes (the “Amended and Restated Secured Notes”). Pursuant to the Amended and Restated Secured Notes, the due date was extended to February 28, 2024 12 198,439 29,419 169,020 1.03 1,200,000 204,392 174,090 30,302 As of December 31, 2022 and 2021, the Company recorded accrued interest in the amount of zero 0 24,181 18,272 36,453 18,181 36,453 Note Payable 5,000,000 November 30, 2021 6 188,485 501,370 493,192 493,192 On February 11, 2021, the Company entered into an amendment to the Promissory Note that extended the Maturity Date to November 30, 2022 6 74,054 298,178 On May 17, 2022, the Company entered into a second amendment to the Promissory Note that extended the Maturity Date to November 30, 2023 6 12 47,115 299,178 Effective December 30, 2022, the Company entered into a third amendment to the Promissory Note. Pursuant to the third amendment, the Company’s obligations under the Promissory Note were secured by the Security Agreement. To secure the Company’s obligations under each of the Amended and Restated Secured Notes and the Promissory Note, the Company entered into a Security Agreement with the Holder, pursuant to which the Company granted a lien on all assets of the Company (the “Collateral”) for the benefit of the Holder. Upon an Event of Default (as defined in the Amended and Restated Secured Notes and Promissory Note, respectively) the Holder may, among other things, collect or take possession of the Collateral, proceed with the foreclosure of the security interest in the Collateral or sell, lease, or dispose of the Collateral. For the three and six months ended December 31, 2022, discount amortization of $ 74,621 149,242 74,274 148,548 4,726,390 Finance Agreement 1,139,875 6.69 96,220 466,625 227,598 For the three and six months ended December 31, 2022, the Company recorded total interest expense in the amount of $ 2,782 Total interest expense recorded for the three and six months ended December 31, 2022, was $ 92,892 188,477 93,382 183,121

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	6 Months Ended
	Dec. 31, 2022
Equity [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 8 — STOCKHOLDERS’ EQUITY Preferred Stock 10,000,000 0.0001 0 Common Stock 100,000,000 0.0001 55,705,521 53,007,082 Voting — Dividends — Liquidation Rights — Purchase Agreement with Lincoln Park Capital On July 8, 2020, we entered into a purchase agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which the Company may sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $ 20,000,000 August 1, 2023 In consideration for entering into the Purchase Agreement, we issued 139,567 During the six months ended December 31, 2022 and 2021, we did no Common Stock Issuances On July 14, 2022, certain of our warrant holders exercised warrants to purchase 1,250,000 1,625,000 2,762,500 2.21 198,439 2,698,439 419,182 Acquisition of Enochian Biopharma Inc. / Contingently issuable shares — no Acquisition of Enochian Denmark — 17,414 167,639 0 Stock-based Compensation The Company recognizes compensation costs for stock option awards to employees and directors based on their grant-date fair value. The value of each stock option is estimated on the date of grant using the Black-Scholes option-pricing model. The weighted-average assumptions used to estimate the fair values of the stock options granted using the Black-Scholes option-pricing model are as follows in the three months ended December 31, 2022: Summary of weighted-average assumptions used to estimate the fair values of the stock options granted Enochian Expected term (in years) 5.3 6.5 Volatility 84.66 90.75 Risk free interest rate 2.70 4.14 Dividend yield 0 The Company recognized stock-based compensation expense related to the options of $ 819,955 1,845,963 2,043,292 4,771,267 4,990,165 Plan Options On February 6, 2014, the Board adopted the Company’s 2014 Equity Incentive Plan (the “2014 Plan”), and the Company had reserved 1,206,000 On October 30, 2019, the Board approved and on October 31, 2019, the Company’s stockholders adopted Enochian’s 2019 Equity Incentive Plan (the “2019 Plan”), which replaced the 2014 Plan. The 2019 Plan authorized options to be awarded to not exceed the sum of (1) 6,000,000 new shares, and (2) the number of shares available for the grant of awards as of the effective date under the 2014 Plan plus any options related to awards that expire, are terminated, surrendered, or forfeited for any reason without issuance of shares under the 2014 Plan after the effective date of the 2019 Plan. Pursuant to the 2019 Plan, the Company granted options to purchase 178,000 120,900 3,130,200 During the three and six months ended December 31, 2022, the Company granted options to purchase zero 0 184,800 no During the three and six months ended December 31, 2022, the Company granted options to purchase zero 0 73,200 no During the three and six months ended December 31, 2022, the Company granted options to purchase 159,959 210,917 36,727 63,462 During the three and six months ended December 31, 2022, the Company did no 21,979 17,500 60,000 All of the above options are exercisable at the market price of the Company’s Common Stock on the date of the grant. To date the Company has granted options under the 2014 Plan and 2019 Plan (“Plan Options”) to purchase 5,475,559 2,310,289 A summary of the status of the Plan Options outstanding at December 31, 2022, is presented below : Summary of stock options outstanding Options Outstanding Options Exercisable Exercise Price Ranges Number Outstanding Weighted Average Remaining Contractual Life (years) Weighted Average Exercise Price Number Exercisable Weighted Average Remaining Contractual Life (years) Weighted Average Exercise Price $ 1.00 4.50 860,273 8.97 $ 2.40 217,064 6.83 $ 3.21 $ 4.51 6.50 3,169,769 8.20 $ 4.83 1,153,876 7.59 $ 5.26 $ 6.51 8.00 803,393 7.70 $ 8.02 604,414 7.24 $ 7.94 Total 4,833,436 8.26 $ 4.93 1,975,354 7.40 $ 5.85 A summary of the status of the Plan Options at December 31, 2022, and changes since July 1, 2022, are presented below: Summary of stock option activity Shares Weighted Average Exercise Average Remaining Life Weighted Average Intrinsic Outstanding at beginning of period 4,307,820 $ 5.37 8.55 $ — Granted 646,917 $ 2.07 Exercised — $ — Forfeited (121,300 ) $ 5.30 Expired/Canceled — $ — Outstanding at end of period 4,833,436 $ 4.93 8.26 $ — Exercisable at end of period 1,975,354 $ 5.85 7.40 $ — At December 31, 2022, the Company had 1,975,354 0 Common Stock Purchase Warrants A summary of the warrants outstanding at December 31, 2022, and changes since July 1, 2022, are presented below: Summary of common stock purchase warrants outstanding Shares Weighted Average Exercise Weighted Average Remaining Outstanding at beginning of period 1,250,000 $ 1.30 1.02 Granted — $ — — Exercised (1,250,000 ) $ 1.30 — Cancelled/Expired — $ — — Outstanding and exercisable at end of period — $ — — Restricted Stock Units (RSUs) The Company recognized stock-based compensation expense related to RSUs of zero 0 255,340 258,331

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 9 — COMMITMENTS AND CONTINGENCIES Commitments On July 9, 2018, the Company entered into a consulting agreement with G-Tech Bio, LLC, a California limited liability company (“G-Tech”) to assist the Company with the development of the gene therapy and cell therapy modalities for the prevention, treatment, and amelioration of HIV in humans, and with the development of a genetically enhanced Dendritic Cell for use as a wide spectrum platform for various diseases (including but not limited to cancers and infectious diseases) (the “G-Tech Agreement”). G-Tech was entitled to consulting fees for 20 months, with a monthly consulting fee of not greater than $ 130,000 On January 31, 2020, the Company entered into a Statement of Work and License Agreement (the “HBV License Agreement”) by and among the Company, G-Tech, and G Health Research Foundation, a not for profit entity organized under the laws of California doing business as Seraph Research Institute (“SRI”) (collectively the “Licensors”), whereby the Company acquired a perpetual, sublicensable, exclusive license (the “HBV License”) for a treatment under development (the “Treatment”) aimed to treat Hepatitis B Virus (HBV) infections. The HBV License Agreement states that in consideration for the HBV License, the Company shall provide cash funding for research costs and equipment and certain other in-kind funding related to the Treatment over a 24 month period, and provides for an up-front payment of $ 1.2 2 1.2 The cash funding for research costs pursuant to the HBV License Agreement consisted of monthly payments amounting to $144,500 that covered scientific staffing resources to complete the project as well as periodic payments for materials and equipment needed to complete the project. There were no payments made after January 31, 2022. During the three and six months ended December 31, 2022 the Company paid a total of zero 0 433,500 867,000 0 0 1,500,000 On April 18, 2021, the Company entered into a Statement of Work and License Agreement (the “License Agreement”), by and among the Company, G-Tech and SRI (collectively, the “Licensors”), whereby the Company acquired a perpetual sublicensable, exclusive license (the “Development License”) to research, develop, and commercialize certain formulations which are aimed at preventing and treating pan-coronavirus or the potential combination of the pan-coronavirus and pan-influenza, including the SARS-coronavirus that causes COVID-19 and pan-influenza (the “Prevention and Treatment”). The License Agreement was entered into pursuant to the existing Framework Agreement between the parties dated November 15, 2019. The License Agreement states that in consideration for the Development License, the Company shall provide cash funding for research costs and equipment and certain other in-kind funding related to the Prevention and Treatment over a 24-month period. Additionally, the License Agreement provides for an up-front payment of $ 10,000,000 760,000 The License Agreement provides for cooperation related to the development of intellectual property related to the Prevention and Treatment and for a 3% royalty to G Tech on any net sales that may occur under the License Agreement. For both the three and six months ended December 31, 2022, the Company paid zero 0 75,000 150,000 On August 25, 2021, the Company entered into an ALC Patent License and Research Funding Agreement in the HIV Field (the “ALC License Agreement”) with Serhat Gümrükcü and SRI (collectively, the “Licensors”) whereby the Licensors granted the Company an exclusive, worldwide, perpetual, fully paid-up, royalty-free license, with the right to sublicense, proprietary technology subject to a U.S. patent application, to make, use, offer to sell, sell or import products for use solely for the prevention, treatment, amelioration of or therapy exclusively for HIV in humans, and research and development exclusively relating to HIV in humans; provided the Licensors retained the right to conduct HIV research in the field. Pursuant to the ALC License Agreement, the Company granted a non-exclusive license back to the Licensors, under any patents or other intellectual property owned or controlled by the Company, to the extent arising from the ALC License, to make, use, offer to sell, sell or import products for use in the diagnosis, prevention, treatment, amelioration or therapy of any (i) HIV Comorbidities and (ii) any other diseases or conditions outside the HIV Field. The Company made an initial payment to SRI of $ 600,000 600,000 G-Tech and SRI are controlled by Serhat Gümrükcü and Anderson Wittekind, shareholders of the Company. Shares held for non-consenting shareholders 17,414 0 Service Agreements – The Company has a consulting agreement for services of a Senior Medical Advisor for up to $210,000 per year on a part-time basis. Contingencies Securities Class Action Litigation Federal Derivative Litigation State Derivative Litigation On October 21, 2022, the Company filed a Complaint in the Superior Court of the State of California for the County of Los Angeles against Serhat Gümrükcü, William Anderson Wittekind, G-Tech Bio LLC, SG & AW Holdings LLC, and Seraph Research Institute. The Complaint alleges that the defendants engaged in a “concerted, deliberate scheme to alter, falsify, and misrepresent to the Company the results of multiple studies supporting its [Hepatitis B] and SARS-CoV-2/influenza pipelines.” Specifically, “Defendants manipulated negative results to reflect positive outcomes from various studies, and even fabricated studies out of whole cloth.” As a result of the defendants’ conduct, the Company claims that it “paid approximately $25 million to Defendants and third-parties that it would not otherwise have paid.” The defendants have not yet answered the allegations set forth in the Company’s complaint. On December 28, 2022, the Company received a demand letter on behalf of Weird Science LLC (“Weird Science”), William Anderson Wittekind, the William Anderson Wittekind 2020 Annuity Trust, the William Anderson Wittekind 2021 Annuity Trust, the Dybul 2020 Angel Annuity Trust, and the Ty Mabry 2021 Annuity Trust alleging that the Company breached the February 16, 2018 Investor Rights Agreement between the Company, Weird Science, and RS Group ApS. Specifically, the demand letter alleges that the Company “breached its obligations under the Investor Rights Agreement to provide the requisite thirty days’ notice” to Holders of Registrable Securities in connection with SEC Form S-3 filings on July 13, 2020 and February 11, 2022 and demands over $64 million in damages. The Company denies these allegations and intends to vigorously defend against this claim. On March 1, 2021, former Enochian BioSciences Chief Financial Officer, Robert Wolfe and his company, Crossfield, Inc., filed a Complaint in the U.S. District Court for the District of Vermont against the Company, Enochian BioSciences Denmark ApS, and certain directors and officers. In the Complaint, Mr. Wolfe and Crossfield, Inc. asserted claims for abuse of process and malicious prosecution, alleging, inter alia, that the Company lacked probable cause to file and prosecute an earlier action, and sought millions of dollars of compensatory damages, as well as punitive damages. The allegations in the Complaint relate to an earlier action filed by the Company and Enochian BioSciences Denmark ApS in the Vermont Superior Court, Orange Civil Division. On March 3, 2022, the court partially granted the Company’s motion to dismiss, dismissing the abuse of process claim against all defendants and all claims against Mark Dybul and Henrik Grønfeldt-Sørensen. On November 29, 2022, the Company filed a motion for summary judgment with respect to the sole remaining claim of malicious prosecution. The Company denies the allegations set forth in the Complaint and will continue to vigorously defend against the remaining claim.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	6 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 10 — RELATED PARTY TRANSACTIONS There were no 718,500 3,537,000

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 11 — SUBSEQUENT EVENTS In accordance with ASC 855-10, the Company performed a review of events subsequent to the balance sheet date through the date of this report and determined that there were no such events requiring recognition or disclosure.

THE BUSINESS AND SUMMARY OF S_2

THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Business	Business
Going Concern	Going Concern 216,502,705
Basis of Presentation	Basis of Presentation
Consolidation	Consolidation
Reclassification	Reclassification 193,137 242,330 .
Accounting Estimates	Accounting Estimates
COVID-19 Update	COVID-19 Update The full extent to which the COVID-19 pandemic may impact our business and operations is subject to future developments, which are uncertain and difficult to predict. We continue to monitor the impact of the COVID-19 pandemic on our business and operations and will seek to adjust our activities as appropriate. In addition, the pandemic could result in significant and prolonged disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect the financial resources available to us.
Functional Currency & Foreign Currency Translation	Functional Currency & Foreign Currency Translation
Cash and Cash Equivalents	Cash and Cash Equivalents 3,830,530 8,805,495
Property and Equipment	Property and Equipment
Intangible Assets	Intangible Assets Definite life intangible assets include patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 350, “Goodwill and Other Intangible Assets”. Intangible assets are recorded at cost. Patent costs consist of costs incurred to acquire the underlying patent. If it is determined that a patent will not be issued, the related remaining capitalized patent costs are charged to expense. Intangible assets are amortized on a straight-line basis over their estimated useful life. The estimated useful life of patents is twenty years from the date of application. Indefinite life intangible assets include license agreements and goodwill. The Company accounts for indefinite life intangible assets in accordance with ASC 350, “Goodwill and Other Intangible Assets”. License agreement costs represent the fair value of the license agreement on the date acquired and are tested annually for impairment, as well as whenever events or changes in circumstances indicate the carrying value may not be recoverable.
Goodwill	Goodwill th
Impairment of Goodwill and Indefinite Lived Intangible Assets	Impairment of Goodwill and Indefinite Lived Intangible Assets For indefinite-lived intangible assets, such as licenses acquired as an IPR&D asset, on an annual basis we determine the fair value of the asset and record an impairment loss, if any, for the excess of the carrying value of the asset over its fair value. For the year ended June 30, 2022, the carrying value of the licenses acquired as an IPR&D asset exceeded its fair value. Therefore, the Company recorded an impairment loss of $ 93,253,000 The carrying value of IPR&D and goodwill at December 31, 2022, was $ 61,571,000 11,640,000
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell and would no longer be depreciated. The depreciable basis of assets that are impaired and continue in use are their respective fair values.
Leases	Leases Rent expense for operating leases is recognized on a straight-line basis, unless the operating lease right of use assets have been impaired, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the condensed consolidated statements of operations. For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease right-of-use assets on a straight-line basis over the remaining lease term with rent expense still included in general and administrative expenses in the unaudited condensed consolidated statements of operations. The Company has elected the practical expedient to not separate lease and non-lease components. The Company’s non-lease components are primarily related to property maintenance, insurance, and taxes, which vary based on future outcomes, and thus are recognized in general and administrative expenses when incurred (see Note 6.)
Research and Development Expenses	Research and Development Expenses 325,959 2,931,334 2,337,222 5,392,658
Income Taxes	Income Taxes
Loss Per Share	Loss Per Share 4,833,436 7,125,894
Fair Value of Financial Instruments	Fair Value of Financial Instruments
Stock Options and Restricted Share Units	Stock Options and Restricted Share Units
Stock-Based Compensation	Stock-Based Compensation 819,955 1,845,963 2,043,292 4,771,267
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	6 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Summary of property and equipment	Summary of property and equipment Useful Life December 31, 2022 June 30, 2022 Lab Equipment and Instruments 4 7 $ 570,157 $ 546,524 Leasehold Improvements 10 224,629 224,629 Furniture, Fixtures and Equipment 4 7 172,861 172,861 Total 967,647 944,014 Less Accumulated Depreciation (411,731 ) (357,478 ) Net Property and Equipment $ 555,916 $ 586,536

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	6 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of life intangible assets	Schedule of life intangible assets Useful Life June 30, Period Change Effect of Currency Translation December 31, Definite Life Intangible Assets Patents 20 $ 279,257 $ — $ 6,163 $ 285,420 Less Accumulated Amortization (234,989 ) (2,993 ) (5,354 ) (243,336 ) Net Definite-Life Intangible Assets $ 44,268 $ (2,993 ) $ 809 $ 42,084 Indefinite Life Intangible Assets License Agreement $ 61,571,000 — — $ 61,571,000 Goodwill 11,640,000 — — 11,640,000 Total Indefinite Life Intangible Assets $ 73,211,000 — — $ 73,211,000
Schedule of expected future amortization expense	Schedule of expected future amortization expense Year ending June 30, 2023 $ 8,883 2024 11,067 2025 11,067 2026 11,067 Total $ 42,084

LEASES (Tables)

LEASES (Tables)	6 Months Ended
	Dec. 31, 2022
Leases
Lease commitments	Lease commitments Year Ending June 30 th Lease Expense 2023 $ 120,002 2024 246,004 2025 253,384 2026 260,985 2027 313,836 Less imputed interest (109,538 ) Total $ 1,084,673
Schedule of net operating lease expenses	Schedule of net operating lease expenses For the Three Months Ended For the Six Months Ended December 31, December 31, 2022 2021 2022 2021 Operating Lease Expense $ 96,730 $ 84,113 $ 140,660 $ 168,196 Sub lease Income (53,310 ) — (106,620 ) — Total Net Lease Expense $ 43,420 $ 84,113 $ 34,040 $ 168,196

STOCKHOLDERS_ EQUITY (Tables)

STOCKHOLDERS’ EQUITY (Tables)	6 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Summary of weighted-average assumptions used to estimate the fair values of the stock options granted	Summary of weighted-average assumptions used to estimate the fair values of the stock options granted Enochian Expected term (in years) 5.3 6.5 Volatility 84.66 90.75 Risk free interest rate 2.70 4.14 Dividend yield 0
Summary of stock options outstanding	Summary of stock options outstanding Options Outstanding Options Exercisable Exercise Price Ranges Number Outstanding Weighted Average Remaining Contractual Life (years) Weighted Average Exercise Price Number Exercisable Weighted Average Remaining Contractual Life (years) Weighted Average Exercise Price $ 1.00 4.50 860,273 8.97 $ 2.40 217,064 6.83 $ 3.21 $ 4.51 6.50 3,169,769 8.20 $ 4.83 1,153,876 7.59 $ 5.26 $ 6.51 8.00 803,393 7.70 $ 8.02 604,414 7.24 $ 7.94 Total 4,833,436 8.26 $ 4.93 1,975,354 7.40 $ 5.85
Summary of stock option activity	Summary of stock option activity Shares Weighted Average Exercise Average Remaining Life Weighted Average Intrinsic Outstanding at beginning of period 4,307,820 $ 5.37 8.55 $ — Granted 646,917 $ 2.07 Exercised — $ — Forfeited (121,300 ) $ 5.30 Expired/Canceled — $ — Outstanding at end of period 4,833,436 $ 4.93 8.26 $ — Exercisable at end of period 1,975,354 $ 5.85 7.40 $ —
Summary of common stock purchase warrants outstanding	Summary of common stock purchase warrants outstanding Shares Weighted Average Exercise Weighted Average Remaining Outstanding at beginning of period 1,250,000 $ 1.30 1.02 Granted — $ — — Exercised (1,250,000 ) $ 1.30 — Cancelled/Expired — $ — — Outstanding and exercisable at end of period — $ — —

THE BUSINESS AND SUMMARY OF S_3

THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Jun. 30, 2022
Accounting Policies [Abstract]
Accumulated deficit	$ 216,502,705		$ 216,502,705		$ 204,345,197
General and administrative expenses		$ 193,137		$ 242,330
Cash held in financial institutions	3,830,530		3,830,530		8,805,495
Goodwill impairment loss					93,253,000
IPR&D	61,571,000		61,571,000		61,571,000
Goodwill	11,640,000		11,640,000		$ 11,640,000
Research and development expense	325,959	2,337,222	$ 2,931,334	$ 5,392,658
Potential dilutive shares			4,833,436	7,125,894
Stock-based compensation	$ 819,955	$ 2,043,292	$ 1,845,963	$ 4,771,267

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ 4,457,748	$ 6,582,941	$ 12,157,508	$ 16,994,910
Cash and cash equivalents	4,118,896	$ 13,707,907	4,118,896	$ 13,707,907	$ 9,172,142	$ 20,664,410
Accumulated deficit	$ 216,502,705		$ 216,502,705		$ 204,345,197

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details) - USD ($)	6 Months Ended
	Dec. 31, 2022	Jun. 30, 2022
Property, Plant and Equipment [Line Items]
Total	$ 967,647	$ 944,014
Less Accumulated Depreciation	(411,731)	(357,478)
Net Property and Equipment	555,916	586,536
Lab Equipment And Instruments [Member]
Property, Plant and Equipment [Line Items]
Total	570,157	546,524
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Total	$ 172,861	172,861
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Useful Life	10 years
Total	$ 224,629	$ 224,629
Minimum [Member] | Lab Equipment And Instruments [Member]
Property, Plant and Equipment [Line Items]
Useful Life	4 years
Minimum [Member] | Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Useful Life	4 years
Maximum [Member] | Lab Equipment And Instruments [Member]
Property, Plant and Equipment [Line Items]
Useful Life	7 years
Maximum [Member] | Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Useful Life	7 years

PROPERTY AND EQUIPMENT (Detai_2

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 27,338	$ 27,990	$ 54,253	$ 55,796

INTANGIBLE ASSETS (Details)

INTANGIBLE ASSETS (Details) - USD ($)	6 Months Ended
	Dec. 31, 2022	Jun. 30, 2022
Finite-Lived Intangible Assets [Line Items]
Definite-life intangible assets	$ 42,084	$ 44,268
Period Change	(2,993)
Effect of Currency Translation	809
Indefinite Life Intangible Assets	73,211,000	73,211,000
Period Changes
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life	20 years
Definite-life intangible assets	$ 285,420	279,257
Period Change
Effect of Currency Translation	6,163
Accumulated Amortization [Member]
Finite-Lived Intangible Assets [Line Items]
Period Change	(2,993)
Effect of Currency Translation	(5,354)
Accumulated Amortization	(243,336)	(234,989)
Licensing Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Indefinite Life Intangible Assets	61,571,000	61,571,000
Period Changes
Goodwill [Member]
Finite-Lived Intangible Assets [Line Items]
Indefinite Life Intangible Assets	$ 11,640,000	$ 11,640,000

INTANGIBLE ASSETS (Details 1)

INTANGIBLE ASSETS (Details 1) - USD ($)	Dec. 31, 2022	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
2023	$ 8,883
2024	11,067
2025	11,067
2026	11,067
Total	$ 42,084	$ 44,268

INTANGIBLE ASSETS (Details Narr

INTANGIBLE ASSETS (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Definite-life intangible assets	$ 42,084		$ 42,084		$ 44,268
Amortization expense	1,507	$ 3,814	2,993	$ 7,741
Goodwill impairment loss					$ 93,253,000
Impairment of intangible asset	$ 0		$ 0

LEASES (Details)

LEASES (Details)	Dec. 31, 2022 USD ($)
Leases
2023	$ 120,002
2024	246,004
2025	253,384
2026	260,985
2027	313,836
Less imputed interest	(109,538)
Total	$ 1,084,673

LEASES (Details 1)

LEASES (Details 1) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Leases
Operating Lease Expense	$ 96,730	$ 84,113	$ 140,660	$ 168,196
Sub lease Income	(53,310)		(106,620)
Total Net Lease Expense	$ 43,420	$ 84,113	$ 34,040	$ 168,196

LEASES (Details Narrative)

LEASES (Details Narrative) - USD ($)		1 Months Ended		3 Months Ended		6 Months Ended
	Nov. 13, 2017	Jun. 20, 2022	Jun. 19, 2018	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Leases
Lease premises, description	On November 13, 2017, the Company entered into a Lease Agreement for a term of five years and two months from November 1, 2017, with Plaza Medical Office Building, LLC, a California limited liability company, as landlord, (the “Landlord”), pursuant to which the Company agreed to lease from the Landlord approximately 2,325 rentable square feet. The base rent increased by 3% each year, and ranged from approximately $8,719 per month for the first year to $10,107 per month for the two months of the sixth year. The lease was terminated early without penalties or additional costs as of September 30, 2022,		On June 19, 2018, the Company entered into a Lease Agreement for a term of ten years from September 1, 2018, with Century City Medical Plaza Land Co., Inc., pursuant to which the Company agreed to lease approximately 2,453 rentable square feet. On February 20, 2019, the Company entered into an Addendum to the original Lease Agreement with an effective date of December 1, 2019, where it expanded the lease area to include another 1,101 square feet for a total rentable 3,554 square feet. The base rent increases by 3% each year, and ranges from $17,770 per month for the first year to $23,186 per month for the tenth year. The equalized monthly lease expense for the term of the lease is $20,050.
Leasehold improvements	$ 70,800
Weighted-average remaining term				4 years 8 months 1 day		4 years 8 months 1 day
Weighted-average discount rate				4.03%		4.03%
Sublease agreement description		On June 20, 2022, the Company entered into a sublease Agreement with One Health Labs (the “Subtenant”), whereby the Subtenant agreed to lease 3,554 square feet of space currently rented by the Company in Century City Medical Plaza as of June 25, 2022, for a period of 3.5 years with an option to renew for the remaining term of the lease that ends as of June 19, 2028. The base rent is $17,770 per month plus $750 towards utility fees that are part of the original lease agreement and will increase by 3% each year over the term of the sub-lease. The Company received a total of $57,022 on July 1, 2022 after execution of the sublease to cover the first month rent, utility fee and deposit. The first sublease payment began on August 1, 2022.
General and administrative expense				$ 43,420	$ 84,113	$ 34,040	$ 168,196

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative) - USD ($)			1 Months Ended					3 Months Ended		6 Months Ended
	Jul. 08, 2021	Feb. 11, 2021	Dec. 30, 2022	Nov. 30, 2022	May 17, 2022	Mar. 17, 2022	Mar. 30, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Jun. 30, 2022
Debt Instrument [Line Items]
Maturity date	Aug. 01, 2023	Nov. 30, 2022
Convertible Notes Payable, Noncurrent								$ 1,200,000	$ 1,200,000	$ 1,200,000	$ 1,200,000
Prepayment shares			169,020
Number of shares issued, value										204,392
Prepaid interest								174,090		174,090
Accrued interest								30,302		30,302
Accrued interest amount								0	24,181	0	24,181
Interest Expense, Other								18,272	18,181	36,453	36,453
Issuance of common stock					$ 299,178
Interest at the fixed rate		6%		6.69%
Shares issued		74,054			47,115
Market price		$ 298,178
Unsecured note principal amount				$ 1,139,875
Monthly installments				$ 96,220
Repayment on finance agreement								466,625	227,598	466,625	227,598
Interest expense related to agreement								2,782		2,782
interest expense								92,892	93,382	188,477	183,121
Convertible Notes Payables [Member]
Debt Instrument [Line Items]
Principal amount								$ 600,000		$ 600,000
Stock price			$ 1.03					$ 0.0001		$ 0.0001
Maturity date										Feb. 06, 2023
Interest rate										6%
Debt Instrument, Convertible, Conversion Price								$ 12		$ 12
Secured Notes [Member]
Debt Instrument [Line Items]
Maturity date			Feb. 28, 2024
Interest rate			12%
Number of shares issued			198,439
Number of shares issued			29,419
Obligation value			$ 1,200,000
Note Payable [Member]
Debt Instrument [Line Items]
Principal amount							$ 5,000,000
Maturity date							Nov. 30, 2021
Interest rate							6%
Stock issued for debt conversion, shares							188,485
Stock issued for debt conversion							$ 501,370
Issuance of common stock							$ 493,192			$ 493,192
Promissory Note [Member]
Debt Instrument [Line Items]
Maturity date						Nov. 30, 2023
Discount amortization								$ 74,621	$ 74,274	149,242	$ 148,548
Debt net of discount								$ 4,726,390		$ 4,726,390
Promissory Note [Member] | Minimum [Member]
Debt Instrument [Line Items]
Interest at the fixed rate						6%
Promissory Note [Member] | Maximum [Member]
Debt Instrument [Line Items]
Interest at the fixed rate						12%

STOCKHOLDERS' EQUITY (Details)

STOCKHOLDERS' EQUITY (Details) - Enochian Biosciences [Member]	6 Months Ended
	Dec. 31, 2022
Dividend yield	0%
Minimum [Member]
Expected term (in years)	5 years 3 months 18 days
Volatility	84.66%
Risk free interest rate	2.70%
Maximum [Member]
Expected term (in years)	6 years 6 months
Volatility	90.75%
Risk free interest rate	4.14%

STOCKHOLDERS' EQUITY (Details 1

STOCKHOLDERS' EQUITY (Details 1) - Share-Based Payment Arrangement, Option [Member] - $ / shares	6 Months Ended
	Dec. 31, 2022	Jun. 30, 2022
Option Indexed to Issuer's Equity [Line Items]
Options Outstanding, Number Outstanding	4,833,436	4,307,820
Options Outstanding, Weighted Average Remaining Contractual Life (years)	8 years 3 months 3 days
Options Outstanding, Weighted Average Exercise Price	$ 4.93	$ 5.37
Options Exercisable	1,975,354
Options Exercisable, Weighted Average Remaining Contractual Life (years)	7 years 4 months 24 days
Options Exercisable, Weighted Average Exercise Price	$ 5.85
Exercise Price Range 1 [Member]
Option Indexed to Issuer's Equity [Line Items]
Options Outstanding, Number Outstanding	860,273
Options Outstanding, Weighted Average Remaining Contractual Life (years)	8 years 11 months 19 days
Options Outstanding, Weighted Average Exercise Price	$ 2.40
Options Exercisable	217,064
Options Exercisable, Weighted Average Remaining Contractual Life (years)	6 years 9 months 29 days
Options Exercisable, Weighted Average Exercise Price	$ 3.21
Exercise Price Range 2 [Member]
Option Indexed to Issuer's Equity [Line Items]
Options Outstanding, Number Outstanding	3,169,769
Options Outstanding, Weighted Average Remaining Contractual Life (years)	8 years 2 months 12 days
Options Outstanding, Weighted Average Exercise Price	$ 4.83
Options Exercisable	1,153,876
Options Exercisable, Weighted Average Remaining Contractual Life (years)	7 years 7 months 2 days
Options Exercisable, Weighted Average Exercise Price	$ 5.26
Exercise Price Range 3 [Member]
Option Indexed to Issuer's Equity [Line Items]
Options Outstanding, Number Outstanding	803,393
Options Outstanding, Weighted Average Remaining Contractual Life (years)	7 years 8 months 12 days
Options Outstanding, Weighted Average Exercise Price	$ 8.02
Options Exercisable	604,414
Options Exercisable, Weighted Average Remaining Contractual Life (years)	7 years 2 months 26 days
Options Exercisable, Weighted Average Exercise Price	$ 7.94
Minimum [Member] | Exercise Price Range 1 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	1
Minimum [Member] | Exercise Price Range 2 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	4.51
Minimum [Member] | Exercise Price Range 3 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	6.51
Maximum [Member] | Exercise Price Range 1 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	4.50
Maximum [Member] | Exercise Price Range 2 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	6.50
Maximum [Member] | Exercise Price Range 3 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	$ 8

STOCKHOLDERS' EQUITY (Details 2

STOCKHOLDERS' EQUITY (Details 2) - Share-Based Payment Arrangement, Option [Member]	6 Months Ended
	Dec. 31, 2022 USD ($) $ / shares shares
Option Indexed to Issuer's Equity [Line Items]
Options Outstanding at beginning of period | shares	4,307,820
Weighted Average Exercise Price, Outstanding at beginning of period | $ / shares	$ 5.37
Weighted Average remaining life	8 years 6 months 18 days
Weighted Average Intrinsic Value, Outstanding at beginning of period | $
Granted | shares	646,917
Weighted average exercise price, Granted | $ / shares	$ 2.07
Exercised | shares
Weighted average exercise price, Exercised | $ / shares
Forfeited | shares	(121,300)
Weighted Average Exercise Price, Forfeited | $ / shares	$ 5.30
Cancelled/Expired | shares
Weighted Average Exercise Price, Expired | $ / shares
Options Outstanding at end of period | shares	4,833,436
Weighted Average Exercise Price, Outstanding at ending of period | $ / shares	$ 4.93
Weighted Average remaining life	8 years 3 months 3 days
Weighted Average Intrinsic Value, Outstanding at end of period | $
Options Exercisable | shares	1,975,354
Options Exercisable, Weighted Average Exercise Price | $ / shares	$ 5.85
Weighted Average Remaining Life, Exercisable	7 years 4 months 24 days
Weighted Average Intrinsic Value, Exercisable end of period | $

STOCKHOLDERS' EQUITY (Details 3

STOCKHOLDERS' EQUITY (Details 3) - Common Stock Purchase Warrants [Member]	6 Months Ended
	Dec. 31, 2022 $ / shares shares
Option Indexed to Issuer's Equity [Line Items]
Outstanding at beginning of period | shares	1,250,000
Weighted average exercise price, Outstanding at beginning of period | $ / shares	$ 1.30
Weighted Average remaining life, Outstanding	1 year 7 days
Granted | shares
Weighted average exercise price, Granted | $ / shares
Exercised | shares	(1,250,000)
Weighted average exercise price, Exercised | $ / shares	$ 1.30
Cancelled/Expired | shares
Weighted average exercise price, Expired | $ / shares
Outstanding at end of period | shares
Weighted average exercise price, Outstanding at end of period | $ / shares

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)				1 Months Ended	3 Months Ended		6 Months Ended
	Jul. 14, 2022	Jul. 08, 2021	Feb. 11, 2021	May 17, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Jun. 30, 2022	Jul. 21, 2020	Jul. 08, 2020	Feb. 06, 2014
Subsidiary, Sale of Stock [Line Items]
Preferred Stock, Shares Authorized					10,000,000		10,000,000		10,000,000
Preferred stock, par value					$ 0.0001		$ 0.0001		$ 0.0001
Preferred stock, shares issued					0		0		0
Preferred stock, shares outstanding					0		0		0
Common stock, shares authorized					100,000,000		100,000,000		100,000,000
Common stock, par value					$ 0.0001		$ 0.0001		$ 0.0001
Common stock, shares issued					55,705,521		55,705,521		53,007,082
Common stock, shares outstanding					55,705,521		55,705,521		53,007,082
Obligation to purchase											$ 20,000,000
Maturity date		Aug. 01, 2023	Nov. 30, 2022
Issued shares			74,054	47,115
Proceeds from common stock				$ 299,178
Extinguishment of contingent consideration liability							$ 419,182
Common stock reserved for issuance					17,414		17,414
Stock based compensation expense					$ 819,955	$ 2,043,292	$ 1,845,963	$ 4,771,267
Unrecognized compensation cost					4,990,165		4,990,165
Intrinsic value					0		0
Stock based compensation expense					819,955	2,043,292	1,845,963	4,771,267
Restricted Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Stock based compensation expense					$ 0	$ 255,340	$ 0	$ 258,331
Share-Based Payment Arrangement, Option [Member]
Subsidiary, Sale of Stock [Line Items]
Number of exercisable shares outstanding					1,975,354		1,975,354
2014 Equity Incentive Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock reserved for issuance												1,206,000
Plan 2019 Options [Member]
Subsidiary, Sale of Stock [Line Items]
Option available to be issued							2,310,289
Option granted							5,475,559
Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Shares purchased	1,250,000
Proceeds from common stock	$ 1,625,000
Non cash earn out distribution	$ 2,762,500
Share Price	$ 2.21
Agreement And Plan Of Merger Agreement Axis [Member] | E B I And Weird Science L L C [Member]
Subsidiary, Sale of Stock [Line Items]
Common shares contingently issuable					0		0
Lincoln Park [Member] | Purchase Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Option available to be issued							0	0
Enochian Bio Pharma Inc [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock issued					198,439		2,698,439
DanDrit Denmark [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock, shares outstanding					167,639		167,639
Enochian Denmark [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock issued					0		0
Employees [Member]
Subsidiary, Sale of Stock [Line Items]
Option granted					0	0	73,200	0
Employees [Member] | N 2019 Equity Incentive Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Option granted					178,000	120,900	178,000	3,130,200
Employees [Member] | Common Stock [Member] | N 2019 Equity Incentive Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Option granted					0	0	184,800	0
Board Of Directors And Scientific Advisory Board [Member]
Subsidiary, Sale of Stock [Line Items]
Option granted					159,959	36,727	210,917	63,462
Consulting Services 1 [Member]
Subsidiary, Sale of Stock [Line Items]
Option granted					0	21,979	0	21,979
Consulting Services 2 [Member]
Subsidiary, Sale of Stock [Line Items]
Option granted						17,500		60,000
Purchase Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Issued shares										139,567

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)				1 Months Ended			3 Months Ended		6 Months Ended
	Sep. 10, 2021	Feb. 06, 2020	Jul. 09, 2019	Aug. 25, 2021	Jan. 31, 2021	Jan. 31, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Nov. 15, 2019
Net Investment Income [Line Items]
Up-front payment											$ 10,000,000
Payment for expenditures											$ 760,000
Prevention and Treatment research							$ 0	$ 75,000	$ 0	$ 150,000
Initial payment				$ 600,000
Paid initial payment	$ 600,000
Remaining shares							17,414		17,414
Number of shares issued for shareholders							0		0
Compensation description									The Company has a consulting agreement for services of a Senior Medical Advisor for up to $210,000 per year on a part-time basis.
G Tech [Member] | License Agreement [Member]
Net Investment Income [Line Items]
Payment for license		$ 1,200,000				$ 1,200,000
Royalty Percentage					2%
Milestone payments							$ 0	0	$ 0	1,500,000
Consulting Agreement [Member] | G Tech [Member]
Net Investment Income [Line Items]
Consulting expenses			$ 130,000
Payment for scientific staffing resources							$ 0	$ 433,500	$ 0	$ 867,000

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Related Party Transactions [Abstract]
Related Party Costs	$ 0	$ 718,500	$ 0	$ 3,537,000